# The Anti-apoptotic Protein HAX-1 Interacts with SERCA2 and Regulates Its Protein Levels to Promote Cell Survival

## Elizabeth Vafiadaki,\* Demetrios A. Arvanitis,\* Stamatis N. Pagakis,\* Vasiliki Papalouka,\* Despina Sanoudou,\* Aikaterini Kontrogianni-Konstantopoulos,<sup>†‡</sup> and Evangelia G. Kranias<sup>\*‡§</sup>

\*Molecular Biology Division, Biomedical Research Foundation, Academy of Athens, Athens, 115 27, Greece; \*Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201; and <sup>§</sup>Department of Pharmacology and Cell Biophysics, College of Medicine, University of Cincinnati, Cincinnati, OH 45267-0575

Submitted June 11, 2008; Revised September 24, 2008; Accepted October 22, 2008 Monitoring Editor: M. Bishr Omary

Cardiac contractility is regulated through the activity of various key  $Ca^{2+}$ -handling proteins. The sarco(endo)plasmic reticulum (SR)  $Ca^{2+}$  transport ATPase (SERCA2a) and its inhibitor phospholamban (PLN) control the uptake of  $Ca^{2+}$  by SR membranes during relaxation. Recently, the antiapoptotic HS-1–associated protein X-1 (HAX-1) was identified as a binding partner of PLN, and this interaction was postulated to regulate cell apoptosis. In the current study, we determined that HAX-1 can also bind to SERCA2. Deletion mapping analysis demonstrated that amino acid residues 575–594 of SERCA2's nucleotide binding domain are required for its interaction with the C-terminal domain of HAX-1, containing amino acids 203-245. In transiently cotransfected human embryonic kidney 293 cells, recombinant SERCA2 was specifically targeted to the ER, whereas HAX-1 selectively concentrated at mitochondria. On triple transfections with PLN, however, HAX-1 massively translocated to the ER membranes, where it codistributed with PLN and SERCA2. Overexpression of SERCA2 abrogated the protective effects of HAX-1 on cell survival, after hypoxia/reoxygenation or thapsigargin treatment. Importantly, HAX-1 overexpression was associated with down-regulation of SERCA2 expression levels, resulting in significant reduction of apparent ER Ca<sup>2+</sup> levels. These findings suggest that HAX-1 may promote cell survival through modulation of SERCA2 protein levels and thus ER Ca<sup>2+</sup> stores.

### INTRODUCTION

The sarco(endo)plasmic reticulum (SR) Ca<sup>2+</sup> transport AT-Pase (SERCA2a) is a critical regulator of Ca<sup>2+</sup> homeostasis and contractility in the heart. During muscle relaxation, SERCA2a transports Ca<sup>2+</sup> from the cytosol into the SR lumen in an ATP-dependent manner (Asahi *et al.*, 2003). Because SERCA2a activity controls both the rate of cytosolic Ca<sup>2+</sup> removal and the degree of SR Ca<sup>2+</sup> load, it represents a major determinant of both cardiac relaxation and contraction (Vangheluwe *et al.*, 2005). Hence, the deteriorated cardiac muscle function associated with heart failure has been largely attributed to the decreased levels and activity of SERCA2a (Hasenfuss *et al.*, 1994; Meyer *et al.*, 1995; Hasenfuss and Pieske, 2002).

The structure of the SERCA pump has been determined by a combination of structural and biochemical information,

This article was published online ahead of print in *MBC in Press* (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08-06-0587) on October 29, 2008.

<sup>‡</sup> These authors contributed equally to this work.

Address correspondence to: Aikaterini Kontrogianni-Konstantopoulos (akons001@umaryland.edu) or Evangelia G. Kranias (litsa.kranias@uc.edu).

Abbreviations used: GFP, green fluorescent protein; GST, glutathione transferase; HAX-1, HS-1 associated protein X-1; HEK, human embryonic kidney; PBS, phosphate-buffered saline; PLN, phospholamban; SERCA2a, sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase; SR, sarcoplasmic reticulum.

306

along with x-ray crystallography studies. The protein is composed of 10 transmembrane helices (M1–M10) and a large cytoplasmic head piece, which is linked to the transmembrane domains by a narrow stalk (Toyoshima *et al.*, 1993; MacLennan *et al.*, 1997; Zhang *et al.*, 1998). The cytoplasmic region of SERCA, which forms the bulk of the protein, can be further divided into three distinct domains: the actuator (A), which is involved in regulation of  $Ca^{2+}$ binding and release; the nucleotide binding (N) region; and the phosphorylation (P) domain.

the phosphorylation (P) domain. The activity of SERCA2a is regulated by phospholamban (PLN), a 52-amino acid transmembrane phosphoprotein in cardiac SR, which interacts with SERCA and reversibly inhibits its affinity for Ca<sup>2+</sup> (Simmerman and Jones, 1998). Detailed cross-linking, site-directed mutagenesis and structural modeling studies have demonstrated that residues in both the cytoplasmic and the transmembrane portions of SERCA2a are involved in direct interaction with PLN (James et al., 1989; Toyofuku et al., 1994a; Kimura et al., 1996; Asahi et al., 1999; Toyoshima et al., 2003). Studies in genetically engineered mouse models with altered PLN expression levels and the identification of PLN mutations in patients with familial dilated cardiomyopathy have demonstrated a critical role of PLN in regulating SR Ca2+ homeostasis and cardiac physiology (Luo et al., 1994; Kadambi et al., 1996; Haghighi et al., 2003, 2006; Schmitt et al., 2003).

Recently, HAX-1, an  $\sim$ 35-kDa ubiquitously expressed protein with antiapoptotic function, was found to interact with PLN, and this association enhanced the protective effects of HAX-1 on cell survival (Vafiadaki *et al.*, 2007).

HAX-1 was originally identified to interact with HS1, a protein specifically expressed in hemopoietic cells with proposed involvement in B cell signal transduction (Suzuki et al., 1997). Subsequent studies have further demonstrated that HAX-1 interacts with a number of cytoskeletal and viral proteins, indicating its involvement in multiple cellular pathways (Vafiadaki et al., 2008). Based on its weak sequence similarity to Nip3 and its homology to Bcl-2 domains BH1 and BH2, HAX-1 was initially proposed to be involved in promoting cell survival. Experimental evidence, however, demonstrated that HAX-1 overexpression provides protection against Fas treatment, gamma-irradiation, serum deprivation, or Bax-induced apoptosis (Suzuki et al., 1997; Sharp et al., 2002). In cardiac myocytes, adenoviral overexpression of HAX-1 was shown to prevent caspase-9 processing and inhibit caspase-3 activation, after hypoxia/reoxygenationinduced cell death (Han et al., 2006), thus indicating that the antiapoptotic effect of HAX-1 is mediated, at least partly, through the mitochondrial apoptotic program.

In the present study, we report that HAX-1 can also bind to SERCA2 independently of PLN. However, overexpression of HAX-1 displaced endogenous SERCA from the membrane fraction and led to SERCA down-regulation in a proteasome-dependent manner, affecting apparent ER Ca<sup>2+</sup> levels. These findings reveal a novel role of HAX-1 in cell survival through regulation of SERCA protein levels.

#### MATERIALS AND METHODS

#### Glutathione Transferase (GST)-Pull Down Assay

GST-pull down assays were performed using cardiac homogenates prepared from PLN-deficient hearts, as described previously (Kontrogianni-Konstantopoulos et al., 2003; Vafiadaki et al., 2007; Arvanitis et al., 2007). The PLNknockout (PLN-KO) mouse was generated, using gene-targeting technology, and its cardiac phenotype has been extensively characterized previously (Luo et al., 1994; Chu et al., 1996; Slack et al., 2001). In brief, frozen cardiac muscle was homogenized in 10 mM NaPO<sub>4</sub>, pH 7.2, 2 mM EDTA, 10 mM NaN<sub>3</sub>, 120 mM NaCl, and 1% NP-40, supplemented with protease inhibitors (Sigma-Aldrich, Munich, Germany). Equal amounts of recombinant GST and GST-HAX-1 proteins were mixed with 0.5 mg of cardiac homogenates at 4°C for 16 h. The samples were washed three times at 4°C with 10 mM NaPO<sub>4</sub>, pH 7.2, 10 mM NaN<sub>3</sub>, 120 mM NaCl, and 0.1% Tween 20, and they were then resuspended in  $2 \times$  SDS Laemmli sample buffer. After SDS-PAGE analysis and transfer to nitrocellulose membrane (Whatman Schleicher and Schuell, Dassel, Germany), the membranes were incubated with monoclonal antibodies to phospholamban or SERCA2 (Affinity Bioreagents, Golden, CO) and were subsequently washed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20 before incubating with a peroxidase-conjugated anti-mouse secondary antibody (Sigma-Aldrich). Immunoreactive bands were detected using enhanced chemiluminescence reagents (GE healthcare, Little Chalfont, Buckinghamshire, United Kingdom).

#### Yeast Two-Hybrid Assay

For the identification of the minimal binding regions of HAX-1 on SERCA2, a series of SERCA2 deletion constructs was generated by PCR amplification, and these were subcloned in the EcoRI/SalI sites of the yeast BD pGBKT7 vector (Matchmaker system; BD Biosciences Clontech, Erembodegem, Belgium). Construct SERCA2-A (amino acids 126-252), which includes the region encoding for the actuator domain (MacLennan et al., 1997; Toyoshima et al., 2000; Dode et al., 2003), was generated using sense primer 1, 5'-CATGGGCAAAGTGTATCGACAG-3' and antisense primer 1, 5'-TTTT-TGCTGAAGGGGTGTTC-3', whereas construct SERCA2-B (amino acids 338-551), which includes the phosphorylation site at amino acid position 351, was generated with sense primer 2, 5'-TGTGGAAACCCTTGGTTGT-3') and antisense primer 2, (5'-ACCCCACTCTCGAATGACAG-3'). Construct SERCA2-C (amino acids 525-732), encoding for the nucleotide binding domain (MacLennan et al., 1997; Toyoshima et al., 2000; Dode et al., 2003) was produced using sense primer 3 (5'-ACCCACATTCGAGTTGGAAG-3') and antisense primer 3 (5'-CCATCTCAGAGGCGGTTTTA-3'). For the generation of deletion constructs within the nucleotide binding domain: 1) sense primer 3 (described above) and antisense primer 4 (5'-CCAACGAAGGTCAGATT-GGT-3') were used for SERCA2-D (amino acids 525–593); and 2) sense primer 4 (5'-ACCAATCTGACCTTCGTTGG-3') and antisense primer 3 (described above) were used for construct SERCA2-E (amino acids 587-732). For construct SERCA2-F (amino acids 575-593), sense primer 5 (5'-ATGCACCTT- GAGGACTCTGC-3') and antisense primer 4 were used, whereas sense primer 3 and antisense primer 5 (5'-TCTTCTCAGTGGGTTGTC-3') were used to generate SERCA2-G (amino acids 525–571). Finally, construct SERCA2-H (amino acids 620–732) was generated using sense primer 6 (5'-ATCATGAT-CACTGGGGACA-3') and antisense primer 3 (see above).

For the identification of the HAX-1 minimal binding region to PLN or SERCA2, a series of successive HAX-1 deletion constructs were generated by polymerase chain reaction (PCR) amplification and subsequent cloning in the EcoRI/XhoI sites of the yeast AD pACT2 vector (Matchmaker system; BD Biosciences Clontech). Constructs HAX-1-A and HAX-1-B have been described previously (Vafiadaki et al., 2007). HAX-1-C construct (amino acids 203-245) was generated using sense primer A (5'-AGCCCAAATCCTATT-TCA-3') and antisense primer A (5'-GCTTCGTGTCGGGTTACTGT-3'), whereas sense primer A and antisense primer B (5'-TCCTCCACTATC-CCATCCTCCACTATC-CCATCTGG-3') were used for construct HAX-1-D (amino acids 203-225). For the generation of HAX-1-E construct (amino acids 222-245), sense primer B (5'-ATAGTGGAGGAGCGCCGGA-3') and antisense primer A were used, whereas for HAX-1-F construct (amino acids 215-245) sense primer C (5'-AGATCACTAAACCAGATG-3') and antisense primer A were used. HAX-1-G construct (amino acids 203-232) was generated using sense primer A and antisense primer C (5'-TGTCCGGCCCTCACTGTC-3'), whereas sense primer D (5'-TAGTGGAGGAGCGCCGGA-3') and antisense primer D (5'-GCTG-GAGGTCTTGGTGATTC-3') were used for HAX-1-H construct (amino acids 222-260). The authenticity of all constructs was confirmed through sequence analysis by Macrogen (Seoul, Korea).

#### Generation and Purification of Recombinant Proteins

The SERCA2 fragment, containing amino acids 525-732, was cloned in the EcoRI/XhoI sites of pGEX 5x-1 (GE Healthcare) vector, whereas the HAX-1 C-terminal fragment containing amino acids 203-279 was cloned in the pGEX 5x-1 and pET28 (Novagen, Nottingham, United Kingdom) vectors as desribed previously (Vafiadaki *et al.*, 2007).

Expression of GST-and His-tagged proteins was induced with 0.1 mM isopropyl-*β*-b-thiogalactopyranoside for 3 h, and proteins were purified by affinity chromatography on glutathione-Sepharose 4B (GE Healthcare) or nickel-nitrilotriacetic acid agarose (QIAGEN, Hilden, Germany) resins following the manufacturer's instructions.

#### In Vitro Binding Assays

Equivalent amounts of GST-SERCA2and GST-protein bound to glutathione matrices were allowed to interact for 16 h at 4°C with 3  $\mu$ g of His-HAX-1 recombinant protein in 50  $\mu$ l of binding buffer containing 50 mM Tris-HCl, pH 7.2, 120 mM NaCl, 10 mM NaN<sub>3</sub>, 2 mM dithiothreitol, and 0.5% Tween 20. The beads were washed three times at 4°C with 50 mM Tris-HCl, pH 7.2, 120 mM NaCl, 10 mM NaN<sub>3</sub>, and 0.1% Tween 20 and were resuspended in 2× SDS Laemmli sample buffer. Samples were analyzed by SDS-PAGE, transferred to nitrocellulose membrane (Whatman Schleicher and Schuell) and probed with a poly-histidine antibody (Sigma-Aldrich) and an anti-rabbit peroxidase-conjugated secondary antibody (GE Healthcare).

#### Titration with Ca<sup>2+</sup>

To study the effect of alterations in Ca<sup>2+</sup> concentration on the interaction between HAX-1 and SERCA2, Ca<sup>2+</sup> titration assays were performed as described previously (Asahi *et al.*, 2000; Vafiadaki *et al.*, 2007). In brief, cardiac extracts (0.3 mg) from wild-type or PLN-KO mice were incubated at room temperature for 5 min with 150  $\mu$ l of reaction buffer (20 mM Tris-HCl, pH 6.8, 100 mM KCl, 5 mM MgCl<sub>2</sub>, 5 mM ATP, 1 mM EGTA, and 5 mM potassium oxalate) containing 10<sup>-8</sup> to 10<sup>-5</sup> M CaCl<sub>2</sub> concentrations, and subsequent GST-pull down assays were carried out as described above.

## Cell Culture, Transfections, and Immunofluorescence Studies

A GST-HAX1 construct containing HAX-1 amino acids 118–260 was generated by PCR by using sense primer 5'-AGACTACGGGAGGGACAGAC-3' and antisense primer D (described above) and was subsequently cloned in the EcoRI/SalI sites of pGEX 5x-1. GST-HAX1 recombinant protein was expressed in bacteria, as described above, and was then used for antibody generation in rabbit (Covance, Denver, PA). The HAX-1 antibody was affinity-purified on GST and GST-HAX-1 columns, as described previously (Kontrogianni-Konstantopoulos *et al.*, 2003).

Human embryonic kidney (HEK) 293 cells (European Collection of Cell Cultures, Salisbury, United Kingdom) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA). Full-length green fluorescent protein (GFP)-PLN, myc-HAX-1 (Vafiadaki *et al.*, 2007), SERCA1 (a kind gift from D. H. MacLennan, Banting and Best Department of Medical Research, University of Toronto, Toronto, Canada), or SERCA2 (National Institutes of Health Mammalian Gene collection, Clone ID 5503508; Invitrogen) constructs were transiently transfected in HEK 293 cells with Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Forty-eight hours after transfection, cells were fixed for 20 min at 25°C with ice-cold methanol, washed three times with phosphatebuffered saline (1× PBS), and permeabilized for 30 min at 25°C in PBS containing 0.1% Triton X-100. After three washes with PBS, cells were incubated with blocking buffer (1× PBS, 1 mg/ml bovine serum albumin, and 10 mM NaN<sub>3</sub>) for 1 h at 25°C, and then primary antibodies (rabbit HAX-1 or SERCA2) diluted in blocking buffer were applied to the cells for 1 h at 25°C. The samples were washed three times with PBS and counterstained for 1 h at 25°C with the appropriate secondary antibody (Alexa Fluor anti-rabbit 488, Alexa Fluor anti-mouse 568, or Alexa Fluor anti-mouse 633; Invitrogen) diluted 1:500 in blocking buffer. After further washes with PBS, samples were mounted with Vectashield medium containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA) and analyzed by confocal microscopy. For MitoTracker CMXRos Red dye (Invitrogen). After three washes with PBS, cells were fixed and permeabilized as described above.

#### Cell Viability Assay

Induction of cell death in transfected HEK 293 cells was performed by incubation with 5 mM H<sub>2</sub>O<sub>2</sub> for 15 h or 1  $\mu$ M thapsigargin (Sigma-Aldrich) for 30 h. After treatment, cell viability was determined by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium (MTT) colorimetric assay, whereas DNA laddering was assessed by gel electrophoresis, as described previously (Vafiadaki *et al.*, 2007). ImageJ software (National Institutes of Health, Bethesda, MD) was used for quantitative analysis of the intensity of the 200-base pair band in the DNA samples.

# HEK 293 Cell Lysate Preparation for Western Blot Analysis

Protein lysates were prepared by lysis of HEK 293 cells in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, and 1% Triton X-100 supplemented with protease inhibitors (Sigma-Aldrich). Lysates were incubated on ice for 10 min and then centrifuged at 13,000 rpm for 5 min to remove cell debris. For Western blot analysis, ~50 µg of cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and immunodetected with SERCA2, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), voltage-dependent anion channel 1 (VDAC1) (Abcam, Cambridge, United Kingdom), calreticuling (Affinity Bioreagents), and calnexin (Santa Cruz Biotechnology, Heidelberg, Germany) antibodies. To investigate the mechanism involved in SERCA2 down-regulation, transfected cells were incubated with 50 nM proteasome inhibitor I (PSI) (Calbiochem, Darmstadt, Germany) or dimethyl sulfoxide (DMSO) for 16 h. Samples were harvested and lysed, as described above, and SERCA2 protein levels were evaluated.

#### Cell Fractionation

Fractionation of HEK 293 cells was performed as described previously (Aga-Mizrachi *et al.*, 2008). Briefly, cells were harvested in buffer A (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, and 1 mM EGTA) supplemented with protease inhibitors (Sigma-Aldrich) and lysed by three freezethaw cycles. Samples were centrifuged at 17,000 × g for 20 min at 4°C, and the supernatant was collected as the cytosolic fraction. The pellet was resuspended in buffer A containing 1% Triton X-100, incubated on ice for 30 min, and centrifuged at 17,000 × g for 20 min at 4°C. The supernatant was then collected as the membrane fraction.

### Ca<sup>2+</sup> Measurements

Transfected HEK 293 cells were loaded with Fura-2 by incubation in 4  $\mu$ M fura-2 acetoxymethyl ester (Invitrogen) in HEPES-buffered solution (HBS) containing 128 mM NaCl, 6 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 5.5 mM glucose, and 10 mM HEPES, pH 7.4, for 35 min at 37°C. Cells were washed in HBS buffer and maintained in this buffer during imaging. Sequential fluorescence images were obtained by measurement of cytosolic Fura-2 emission intensity (510 nm) under dual excitation at 340- and 380-nm wavelengths using the ImageMaster Imaging system (Photon Technology International, Princeton, NJ). Thapsigargin binds to SERCA with high affinity and with a 1:1 stoichiometry. Previous reports have demonstrated that thapsigargin treatment in the range of 1–5  $\mu$ M causes maximal release of Ca<sup>2+</sup> from endoplasmic/sarcoplasmic reticulum vesicles (Lytton et al., 1991; Sagara and Inesi, 1991; Berman, 2000). Consequently, addition of 12 µM thapsigargin in our studies achieved maximal inhibition of SERCA's activity and induced maximal release of Ca2+ from ER stores. Images were analyzed using the Image-Master software (Photon Technology International), which enabled background subtraction and measurement of fluorescence intensity for the time course of the experiment. At least 10-20 individual cells were measured for each experiment.

### RESULTS

# Identification of a Direct Interaction between HAX-1 and SERCA2 and the Effect of $Ca^{2+}$ Concentration

We had previously shown the presence of SERCA2 in GST-HAX-1 pull down samples from cardiac homogenates (Va-

fiadaki *et al.*, 2007), which suggested that either PLN can simultaneously interact with both HAX-1 and SERCA2 or that HAX-1 may bind directly to SERCA2. To determine whether HAX-1 may be able to bind to SERCA2 independently of PLN, we performed pull down assays using cardiac homogenates from the PLN-KO mouse and a GST-HAX-1 recombinant construct containing HAX-1 amino acids 203-279 (Figure 1A), which was shown previously to bind PLN. Western blot analysis revealed that GST-HAX-1 but not control GST-protein was able to absorb native SERCA2 (Figure 1A), demonstrating that the interaction between HAX-1 and SERCA2 can occur independently of the presence of PLN.

To examine whether  $Ca^{2+}$  elevation may also regulate the SERCA2 and HAX-1 interaction, we determined the amount of native SERCA2, associated with GST-HAX-1, in PLN-KO cardiac homogenates at various  $Ca^{2+}$  levels. Previous studies have shown that the PLN/SERCA2a interaction (James *et al.*, 1989; Asahi *et al.*, 2000) and the PLN/HAX-1 interaction (Vafiadaki *et al.*, 2007) may be reduced by elevating  $Ca^{2+}$  concentration. Immunoblot analysis using the SERCA2 and PLN/HAX-1 interactions, increases in  $Ca^{2+}$  concentration caused a concentration-dependent decrease in the amount of SERCA2 interacting with HAX-1 (Figure 1B). Quantitative analysis using ImageJ software revealed an ~44% reduction in the amount of SERCA2 interacting with HAX-1 at pCa 5, compared with the levels observed at pCa 8.

We next performed Ca<sup>2+</sup> titration assays, using wild-type mouse cardiac homogenates, to examine any potential effects of PLN on the SERCA2/HAX-1 interaction. Immunoblot analysis, using the SERCA2 antibody, revealed an ~65% reduction in the amount of SERCA2 that interacted with GST-HAX-1 at pCa 5, relative to the amount bound at pCa 8 (Figure 1C). Notably, the trends of the Ca<sup>2+</sup> titration curves of the SERCA2/HAX-1 interaction were similar in the presence or absence of PLN.

Immunoblot analysis using the PLN antibody was also performed on these samples and identified an ~33% reduction in the amount of PLN interacting with HAX-1 at pCa 5, compared with the amount interacting at pCa 8 (Figure 1D), consistent with our previous findings (Vafiadaki *et al.*, 2007).

#### Determination of the SERCA2 and HAX-1 Minimal Binding Domains Involved in Their Interaction

Having determined that HAX-1 can bind to SERCA2 in PLN-KO cardiac homogenates, we subsequently investigated the region of SERCA2 required for its interaction with HAX-1. To this end, three SERCA2 constructs were generated and assayed in the yeast two-hybrid system for their ability to bind to HAX-1. Because the GST-HAX-1 recombinant protein was shown previously to bind to the cytosolic domain of PLN, we hypothesized that the cytosolic portion of SERCA2 would be also involved in its interaction with HAX-1, and focused our studies on this part of the protein. We generated SERCA2 constructs containing the actuator domain (construct SERCA2-A, amino acids 126-252), the phosphorylation site (construct SERCA2-B, amino acids 338-551) and the nucleotide binding domain (construct SERCA2-C, amino acids 525-732) of the protein. Only the nucleotide binding domain construct was found to interact with HAX-1 in the yeast two-hybrid system, indicating that this C-terminal fragment of SERCA2 is required for binding to HAX-1 (Figure 2A).

To further define the minimal binding region of SERCA2, several overlapping deletion constructs spanning the nucleotide binding domain were generated, that contained



**Figure 1.** HAX-1 binds to native SERCA2 in PLN-KO cardiac homogenates and the interaction is diminished by elevation in  $Ca^{2+}$  concentration. (A) Recombinant GST-HAX-1<sub>aa 203-279</sub> (~30 kDa) and GST (~25 kDa) were separated by SDS-PAGE and visualized by Coomassie Blue staining. Equivalent amounts of GST-HAX-1<sub>aa 203-279</sub> and GST-protein bound to glutathione matrices were incubated with PLN-KO cardiac homogenates. GST-HAX-1<sub>aa 203-279</sub> but not GST bound native SERCA2, as determined by immunoblot analysis with an anti-SERCA2 antibody. (B) GST-pull down assays, using GST-HAX-1 recombinant protein and PLN-KO cardiac homogenates that had been preincubated with different Ca<sup>2+</sup> concentrations, demonstrated a concentration-dependent decrease in SERCA2 binding. Data are expressed as percentage of maximal binding and presented as means  $\pm$  SE (n = 3). A concentration-dependent decrease in SERCA2/HAX-1 (C) or PLN/HAX-1 (D) binding was detected in wild-type mouse cardiac homogenates (n = 4), indicating that the presence or absence of PLN does not affect the SERCA2/HAX-1 binding.

SERCA2 amino acids (aa) 525-732. These allowed us to map the minimal binding region for HAX-1 to SERCA2 between amino acids 575–594 (Figure 2A). Furthermore, in vitro binding assays, using bacterially expressed GST-SERCA2<sub>aa</sub>  $_{525-732}$ and the His-HAX-1<sub>aa</sub>  $_{203-279}$  (~10-kDa recombinant protein) described above (Figure 2B), were performed to confirm the direct interaction between SERCA2 and HAX-1. A larger peptide (~47k Da) than the minimal biding regions of SERCA2 (amino acids 575–593) was used to more readily separate SERCA from the control GST-protein (25 kDa). Equivalent amounts of GST-SERCA2<sub>aa 525-732</sub> and control GST proteins, bound to glutathione matrices, were incubated with affinity-purified His-HAX-1<sub>aa 203-279</sub> protein. Western blot analysis with a histidine-antibody demonstrated



that His-HAX-1 bound specifically to  $\text{GST-SERCA2}_{aa}$   $_{525-732\prime}$  but not to control GST-protein (Figure 2C), confirming that SERCA2 binds directly to HAX-1.

Because the HAX-1 recombinant proteins (GST-HAX-1<sub>aa 203-279</sub> and His-HAX-1<sub>aa 203-279</sub>) that interact with SERCA2 contain the C-terminal region of HAX-1, which was shown previously to bind PLN, we generated several overlapping deletion constructs to further define the HAX-1 amino acids required for its interaction with SERCA2 or PLN. Using the yeast two-hybrid system, HAX-1 amino acids 203-245 were found to bind to either PLN (Vafiadaki et al., 2007) or SERCA2. In contrast, HAX-1 amino acids 203-225 were able to bind to PLN but not to SERCA2 (Figure 3A). None of the other HAX-1 C-terminal deletion constructs (HAX-1-E or HAX-1-H) or the N-terminal construct containing HAX-1's amino acids 1-130 (HAX-1-A) were found to interact with either PLN or SERCA2, indicating that the minimal binding regions of HAX-1 for PLN and SERCA2 include amino acids 203-225, and 203-245, respectively (Vafiadaki et al., 2007; Figure 3A). These findings were also confirmed by pull down assays in cardiac homogenates. Recombinant GST- $HAX1_{aa\ 203-245}$  protein was able to retain both native PLN and SERCA2, whereas GST-HAX1<sub>aa\ 203-225</sub> protein bound only PLN (Figure 3, B and C).

# Analysis of HAX-1 Subcellular Distribution in HEK 293-transfected Cells

HAX-1 has been localized to mitochondria, ER, and nuclear envelope by transient transfections in COS-7, HeLa, and

Figure 2. Amino acids 575-594 within the nucleotide binding domain of SERCA2 are required for binding to HAX-1. (A) To determine the minimal region of SERCA2 required for its association with HAX-1, three constructs (SERCA2-A, SERCA2-B, and SERCA2-C) containing the cytoplasmic regions of SERCA2 were generated and tested for their ability to bind to HAX-1 in yeast. Generation of several overlapping deletion constructs (SERCA2-D-H) for the region contained in construct SERCA2-C mapped the minimal binding domain to SERCA2 amino acids 575-594. (B) Recombinant GST-SERCA2<sub>aa 525-732</sub> (~47 kDa), GST (~25 kDa) and His-HAX-1\_{aa 203-279} ( ${\sim}10$  kDa) were subjected to SDS-PAGE and stained with Coomassie Blue. (C) Equivalent amounts of GST-SERCA2<sub>aa 525-732</sub> and GST recombinant proteins attached to glutathione matrices were incubated with His-HAX-1<sub>aa 203-279</sub>. Bound His-HAX-1<sub>aa 203-279</sub> was detected by Western blot analysis with an anti-Histidine antibody. GST-SERCA2aa 525-732 but not GST-protein bound His-HAX-1<sub>aa 203-279</sub>, demonstrating that binding of SERCA2 to HAX-1 is direct and specific.

DG75 cells (Suzuki et al., 1997; Gallagher et al., 2000; Dufva et al., 2001; Sharp et al., 2002; Yedavalli et al., 2005; Kasashima et al., 2006). Previous studies from our laboratory have demonstrated that overexpression of myc-HAX-1 in HEK 293 cells resulted in a speckled HAX-1 localization pattern, which represented mitochondrial distribution, as determined by its codistribution with the mitochondrial dye MitoTracker (Vafiadaki et al., 2007). Importantly, GFP-PLN and myc-HAX-1 cotransfection resulted in extensive redistribution of HAX-1, which preferentially targeted and colocalized with PLN at the ER compartment (Vafiadaki et al., 2007). To determine whether SERCA2 may also cause a similar change in HAX-1's localization, we performed transient cotransfections of constructs encoding full-length proteins in HEK 293 cells. Forty-eight hours after transfection, immunofluorescence analysis determined the expected preferential ER distribution for SERCA2, as shown by its colocalization with GFP-PLN (Figure 4A). However, in the presence of SERCA2, HAX-1 did not concentrate at the ER membranes but instead exhibited a speckled distribution (Figure 4B), representing mitochondrial localization, as determined by MitoTracker costaining (Figure 4C). Therefore, contrary to PLN, SERCA2 overexpression does not seems to affect the localization of HAX-1. Triple transfections of HEK 293 cells with GFP-PLN, myc-HAX-1, and SERCA2 revealed a preferential ER distribution for HAX-1, most likely due to the presence of PLN, resulting in colocalization of all three proteins at the ER compartment (Figure 4D). Similar findings on the cellular distribution of HAX-1 were also determined using a SERCA1 overexpression construct (data not shown).



binding domain required for PLN or SERCA2 interaction. (A) To delineate the HAX-1 Cterminal region required for binding to either PLN or SERCA2, a series of HAX-1 deletion constructs were generated and tested for their ability to bind to PLN or SERCA2 in yeast. Amino acids 203-225 are required for binding to PLN, whereas a larger region of HAX-1, encompassing amino acids 203-245, is required for its binding to SERCA2. The Bcl-2 homology domains 1 and 2 (BH1 and BH2), PEST sequence and transmembrane domain (TM) of HAX-1 are indicated. (B) Recombinant GST-HAX-1<sub>aa 203-225</sub> (~28 kDa), GST-HAX-1<sub>aa 203-245</sub> (~30 kDa) and GST (~25 kDa) proteins were subjected to SDS-PAGE and stained with Coomassie Blue. (C) To confirm the findings from the yeast two-hybrid system, GST pull-down assays were performed using equivalent amounts of GST-HAx-1aa 203-225/ GST-HAX-1<sub>aa 203-245</sub>, and GST-protein bound to glutathione matrices and cardiac homogenates. Immunoblot analysis using anti-PLN or anti-SERCA2 antibodies determined that GST-HAX-1  $_{\rm aa}$   $_{\rm 203-245}$  binds to both PLN and SERCA2 native proteins, whereas GST-HAx-1<sub>aa 203-225</sub> binds only to PLN.

Figure 3. Determination of HAX-1 minimal

## Evaluation of HAX-1's Antiapoptotic Role in the Presence of SERCA2

Overexpression of HAX-1 has been shown to provide protection against apoptosis (Suzuki et al., 1997; Sharp et al., 2002; Cilenti et al., 2004; Han et al., 2006) and the presence of PLN enhances its antiapoptotic role in HEK 293 cells, subjected to hypoxia (Vafiadaki et al., 2007). To assess whether SERCA expression may also affect the function of HAX-1, we performed transient transfections in HEK 293 cells and induced cell death by exposure to 5 mM  $H_2O_2$  for 15 h. Cell viability assays determined that although HAX-1-transfected cells displayed increased viability compared with control cells transfected with empty vector, this antiapoptotic effect of HAX-1 was abolished in the presence of SERCA2 (Figure 5A). Additionally, SERCA2 overexpression prevented the enhanced cellular protection mediated by coexpression of HAX-1 and PLN (Figure 5A). Similar results were obtained from DNA laddering analysis, which further confirmed that overexpression of SERCA reduces the antiapoptotic activity of HAX-1 and HAX-1/PLN (Figure 5, C and D). These findings suggest that PLN enhances the protective role of HAX-1 against cell death (Vafiadaki et al., 2007), but SERCA2 seems to have an opposite effect on the antiapoptotic capacity of HAX-1.

We next used thapsigargin, a selective inhibitor of SERCA2, that induces apoptosis through ER stress after perturbation of Ca<sup>2+</sup> levels (Thastrup et al., 1990; Lytton et al., 1991) to further evaluate the antiapoptotic role of HAX-1. The HAX-1-transfected cells exhibited increased viability (Figure 5B), and cotransfection with PLN resulted in a further increase in cellular survival (Figure 5B). On the contrary, cotransfection with SERCA2 caused a reduction in cell viability in HAX-1 or in PLN and HAX-1-cotransfected cells (Figure 5B). These data suggest that HAX-1 exhibits a protective effect on cellular survival even upon treatment with another apoptosis-inducing agent, such as thapsigargin. Furthermore, our findings indicate that under these experimental conditions, whereas the presence of PLN induces a stronger protective role for HÂX-1 in the cell, SERCA2 seems to abolish its antiapoptotic capability.

#### HAX-1 Overexpression in HEK 293 Cells Results in Down-Regulation of Endogenous SERCA2 Protein Levels and Reduced ER Ca<sup>2+</sup> Content

The antiapoptotic proteins of the Bcl-2 family, such Bcl-2 and Bcl-xL, have been previously shown to modulate ER Ca<sup>2+</sup> levels (Foyouzi-Youssefi *et al.*, 2000; Pinton *et al.*, 2000; Li *et al.*, 2002; Vanden Abeele *et al.*, 2002). To examine whether



Figure 4. Immunofluorescence analysis of SERCA2, PLN, and HAX-1 proteins in transiently transfected HEK 293 cells. (A) The SERCA2 protein localizes to the ER, as demonstrated by its colocalization with GFP-PLN. SERCA2 was detected with an anti-SERCA2 mAb and Alexa Fluor anti-mouse 568 secondary antibody. Cell nuclei were visualized with DAPI staining. (B and C) Cotransfection of myc-HAX-1 and SERCA2 determined a mitochondrial localization for HAX-1, as indicated by MitoTracker costaining. HAX-1 was detected with a rabbit anti-HAX-1 antibody and Alexa Fluor anti-rabbit 488 secondary antibody, whereas for SERCA2 immunofluorescence Alexa Fluor anti-mouse 568 or 633 secondary antibodies were used, respectively. (D) To the contrary, triple transfections showed that the presence of PLN causes a significant redistribution of HAX-1, thus resulting in colocalization of the three proteins (GFP-PLN, myc-HAX-1, and SERCA2) at the ER. The localization pattern of HAX-1 was detected using rabbit HAX-1 antibody and Alexa Fluor anti-rabbit 568 secondary antibody, whereas Alexa Fluor anti-mouse 633 secondary antibody was used for SERCA2 immunofluorescence. Bar, 5 µm.

the protective role of HAX-1 may be also mediated through regulation of Ca2+ homeostasis, we performed cytosolic Ca<sup>2+</sup> measurements in transiently transfected HEK 293 cells, using the Fura-2 fluorescent indicator. Addition of thapsigargin, an irreversible inhibitor of SERCA activity that leads to passive release of Ca<sup>2+</sup> from ER stores and subsequent increase in the cytosolic Ca<sup>2+</sup> levels (Thastrup *et al.*, 1990; Lytton et al., 1991), was used for indirect determination of ER Ca<sup>2+</sup> content. Previous studies have demonstrated that thapsigargin treatment in the range of 1–5  $\mu$ M results in maximal  $Ca^{2+}$  release from the ER/SR vesicles (Lytton *et al.*, 1991; Sagara and Inesi, 1991; Berman, 2000). In our experimental system, we chose 12  $\mu$ M thapsigargin to achieve maximal inhibition of SERCA's activity and measure immediate and maximal Ca2+ release from the ER stores. Thapsigargin treatment resulted in  $\sim$ 37% reduction in the levels of cytosolic Ca<sup>2+</sup> in HAX-1–overexpressing cells, compared with vector transfected cells (Figure 6A). On the contrary, cotransfection with SERCA2 abolished this inhibitory effect of HAX-1, resulting in a 9% increase in the levels of cytosolic Ca<sup>2+</sup>, compared with cells transfected with vector (Figure 6A). Notably, overexpression of SERCA2 by itself resulted in a further increase in cytosolic Ca<sup>2+</sup> levels ( $\sim$ 40%), compared with vector-transfected cells (Figure 6A). Western blot analysis verified the expression levels of transfected proteins in these studies (Figure 6B).

To determine whether the effect of HAX-1 on ER Ca<sup>2+</sup> levels may be mediated through alterations in the endogenous SERCA2 protein levels, we performed Western blot analysis on HEK 293 cell lysates. To demonstrate the specificity of any observed effects, we also evaluated the expression levels of appropriate marker proteins. Because SERCA2 is an ER protein, and HAX-1 is primarily localized in the mitochondria, we used calreticulin, an ER Ca<sup>2+</sup>-binding protein, and the VDAC1, an outer mitochondrial membrane protein, as markers of the respective organelles. HAX-1 overexpression was found to cause a significant down-regulation (~60%) of the endogenous SERCA2 protein levels, compared with control cells transfected with empty vector (Figure 7, A and B). No significant changes in the endogenous levels of calreticulin, or VDAC1 were observed in these HAX-1–overexpressing cells (Figure 7, A and B). Importantly, RT-PCR analysis did not detect any alterations in SERCA2 mRNA levels, after HAX-1 overexpression (Figure 7C), suggesting that the observed down-regulation of endogenous SERCA2 levels is occurring posttranslationally.

Because previous studies have demonstrated the involvement of the proteasomal pathway in mediating degradation of SERCA2 after calreticulin overexpression in myocardial H9c2 cells (Ahn et al., 2003; Ihara et al., 2005), we examined whether down-regulation of SERCA2 in HAX-1-overexpressing cells may also be occurring in a proteasome-dependent manner. Inhibitors of the proteasomal chymotrypsinlike activity were used previously to demonstrate the proteasomal-mediated degradation of SERCA2 (Ahn et al., 2003; Ihara et al., 2005); consequently, we chose to use such an inhibitor, and in particular PSI, in our studies. As expected, the levels of SERCA2 were reduced by ~59% in HEK 293 cells transfected with HAX-1 in the absence of PSI; on the contrary, treatment with 50 nM PSI restored SERCA2 expression to levels similar to vector-transfected cells (Figure 8, A and B).

Furthermore, to determine whether HAX-1 overexpression may lead to SERCA2 proteasomal degradation through alterations in its subcellular distribution, we fractionated HEK 293-transfected cells into cytosolic and membrane fractions. To demonstrate the purity of the generated fractions, we examined the presence of representative marker proteins in our samples. Because SERCA2 and HAX-1 are membrane proteins of the ER and mitochondria, respectively, we evaluated the subcellular distribution of additional membrane proteins of these organelles. VDAC1, a mitochondrial outer membrane protein and calnexin (CANX), an ER membrane protein were chosen for this analysis mainly because of their membrane distribution in these organelles and their expression in HEK 293 cells. In control, vector-transfected cells,

### A H<sub>2</sub>O<sub>2</sub> treatment

### Thapsigargin treatment



В

**Figure 5.** Overexpression of SERCA inhibits the antiapoptotic effect of HAX-1 in HEK 293 cells. Cells transfected with the indicated constructs were exposed to 5 mM H<sub>2</sub>O<sub>2</sub> (A) or 1  $\mu$ M thapsigargin (B), and cell viability was determined by the MTT assay. Under both treatments, HAX-1-transfected cells exhibited increased cellular viability, compared with control cells. However, this effect seemed to be abolished upon cotransfection with SERCA. Data are presented as mean  $\pm$  SE (n = 4; *t* test, \*p < 0.05). (C) DNA laddering analysis of genomic DNA isolated from transfected HEK 293 cells exposed to H<sub>2</sub>O<sub>2</sub>, determined that the observed changes in cell viability were due to apoptotic cell death. A representative gel from a single experiment is shown. (D) Quantitative analysis of the intensity of the 200-base pair band in all samples shown in C. Data are presented as means  $\pm$  SE (n = 3; *t* test, \*p < 0.05).

SERCA2 was detected only in the membrane fraction. HAX-1 overexpression resulted in reduction of SERCA2 protein levels in the membrane fraction and displacement of a portion of the protein to the cytosolic fraction (Figure 9). This subcellular alteration was specific for SERCA2 as no effects on the subcellular distribution of CANX, VDAC1 or the cytosolic protein  $\beta$ -actin were observed. The displacement in the subcellular distribution of the endogenous SERCA2 protein could therefore lead to its subsequent reduction through the proteasome degradation pathway.

### DISCUSSION

This study is the first to report that HAX-1, a primarily mitochondrial protein with antiapoptotic function, can bind to SERCA2. The interaction between HAX-1 and SERCA2

occurs independently of PLN, and it is diminished by increasing  $Ca^{2+}$  concentration, similar to the PLN/SERCA and PLN/HAX-1 interactions (James *et al.*, 1989; Asahi *et al.*, 2000; Vafiadaki *et al.*, 2007). Furthermore, overexpression of HAX-1 seems to regulate the SERCA2 protein levels and ER  $Ca^{2+}$  stores, which may play an important role in the anti-apoptotic function of HAX-1.

Deletion mapping determined that a region including amino acids 575–594 within the nucleotide binding domain of SERCA2 is required for its interaction with HAX-1. Because the nucleotide binding region is proposed to play a crucial role in determining the high  $Ca^{2+}$  affinity of SERCA2 (Toyofuku *et al.*, 1992, 1993), it is possible that its interaction with HAX-1 may affect the SERCA activity. Previous crosslinking, site-directed mutagenesis and structural modeling studies have shown that residues Lys397-Val402 within the



Figure 6. Overexpression of HAX-1 reduces releasable ER Ca2+ levels. (A) HEK 293 cells were transfected with indicated constructs and were loaded with Fura-2. Treatment of control cells with thapsigargin resulted in release of ER Ca<sup>2+</sup> and subsequent elevation of cytosolic Ca<sup>2+</sup> levels. To the contrary, ER Ca<sup>2+</sup> release was significantly reduced after thapsigargin treatment in HAX-1-overexpressing cells, compared with control cells, whereas cotransfection with SERCA2 abolished this effect. Transfection of SERCA2 by itself resulted in further increase in ER Ca<sup>2+</sup> release, after thapsigargin treatment, compared with control cells. Data are presented as mean  $\pm$  SE (n = 3; *t* test, \*p < 0.05). (B) Western blot analysis of HEK 293 cells transfected with the indicated constructs determined the levels of SERCA2 or myc-HAX-1 overexpressing proteins. The HAX-1 antibody detects both endogenous (arrowhead) and transfected myc-HAX1 protein (arrow), which are different in size due to the presence of the myc tag. Similarly, the SERCA2 antibody detects both the endogenous and overexpressed SERCA2 proteins; these, however, have the same size because there is no tag on the exogenous protein.

cytoplasmic region of SERCA2 are involved in binding to PLN (James *et al.*, 1989; Toyofuku *et al.*, 1994b; Toyoshima *et al.*, 2003). Hence, the interaction with PLN occurs at residues close to the phosphorylation site (Asp 351) of SERCA, whereas HAX-1 binding requires residues within the nucle-otide binding domain.

Immunofluorescence microscopy studies have localized HAX-1 to the mitochondria, endoplasmic reticulum and the nuclear envelope (Suzuki *et al.*, 1997; Gallagher *et al.*, 2000; Dufva *et al.*, 2001; Sharp *et al.*, 2002; Yedavalli *et al.*, 2005; Han *et al.*, 2006; Kasashima *et al.*, 2006). Our transient transfections in HEK 293 cells have demonstrated that recombinant HAX-1 preferentially localizes to mitochondria, whereas, upon cotransfection with PLN, it undergoes cel-



Figure 7. HAX-1 overexpression down-regulates endogenous SERCA2 protein levels. (A) Western blot analysis of HEK 293 cells transfected with the indicated constructs determined a significant reduction in the SERCA2 protein levels as the result of HAX-1 overexpression. HEK 293 cell lysates were separated by SDS-PAGE and incubated with SERCA2, calreticulin (CALRT), VDAC1, or GAPDH antibodies. A representative Western blot from a single experiment is shown. (B) Quantitative analysis of SERCA2, calreticulin (CALRT), VDAC1, or GAPDH antibodies. A representative Western blot from three independent experiments determined a statistically significant down-regulation of SERCA2 protein levels in HAX-1 transfected cells, compared with controls. Data are presented as means  $\pm$  SE (n = 3; *t* test, \*p < 0.05). (C) RT-PCR analysis of HEK 293 cells transfected with the indicated constructs did not identify any changes at SERCA2 mRNA levels.

lular redistribution and colocalizes with PLN at the ER (Vafiadaki *et al.*, 2007). Contrary to the effect of PLN on HAX-1 localization, transient cotransfections with SERCA did not seem to affect HAX-1 subcellular distribution, which was still preferentially targeted to mitochondria. However, as immunofluorescence studies in oligodendrocytes and



**Figure 8.** HAX-1 overexpression promotes proteasome-dependent down-regulation of SERCA2. (A) Immunoblot analysis indicating that the presence of PSI suppressed degradation of SERCA2, promoted by HAX-1, which suggests the involvement of the proteasome pathway in SERCA2 down-regulation. Protein levels of transfected myc-HAX-1 are also shown (arrow), whereas endogenous HAX-1 is indicated by an arrowhead. (B) Quantitative analysis of SERCA2 or GAPDH protein levels determined the occurrence of a statistical significant down-regulation of SERCA2 in HAX-1-transfected cells that had been incubated with DMSO, whereas SERCA2 protein degradation was found to be inhibited in the presence of the proteasome inhibitor PSI. Data are presented as means  $\pm$  SE (n = 3; *t* test, \*p < 0.05).

RBL-2H3 mucosal mast cells have previously determined the close association of SERCA with mitochondria (Simpson and Russell, 1997; Csordas and Hajnoczky, 2001), it is possible that even though there was no direct colocalization of the overexpressed proteins, they may partially colocalize at sites of ER and mitochondrial membrane apposition. Consistent with this, HAX-1 has been shown to be an integral protein of the outer mitochondrial membrane (Kasashima et al., 2006), which may allow it to directly interact with SERCA at sites of close association between mitochondrial and ER membranes. Indeed, high-resolution microscopy approaches have determined the existence of such mitochondrial and ER membrane contact sites, with an estimated 5-20% of mitochondrial surface being in association with ER in HeLa cells (Mannella et al., 1998; Rizzuto et al., 1998). Importantly, the presence of tethering structures that physically link the ER and outer mitochondrial membranes were recently revealed by electron tomography, a finding which



**Figure 9.** HAX-1 overexpression affects the subcellular distribution of SERCA2. Western blot analysis of cytosolic and membrane fractions determined that a portion of the endogenous SERCA2 protein was present in the cytosolic fraction of HAX-1 overexpressing cells. No alterations were found in the subcellular distribution of VDAC1, an outer mitochondrial membrane protein, CANX, an ER membrane protein, or cytosolic  $\beta$ -actin. The subcellular distribution of transfected myc-HAX-1 is also shown (arrow), with the endogenous HAX-1 protein being indicated by an arrowhead. Similar findings were observed in three independent experiments.

further highlights the existence of the ER-mitochondrial contact sites (Csordas *et al.*, 2006). Although the interface area between the two organelles may represent only a small part of the mitochondrial and ER surface, it was proposed that the close apposition of ER and mitochondrial membranes may exert local  $Ca^{2+}$  control and thus insulate mitochondria from moderate increases in  $Ca^{2+}$  levels originated in regions outside the ER-mitochondria junctions (Csordas and Hajnoczky, 2001). Based on its localization and on direct measurements of  $Ca^{2+}$  signals, SERCA was proposed to regulate local  $Ca^{2+}$  microdomains at the ER-mitochondria junctions (Csordas and Hajnoczky, 2001), and the interaction of SERCA with HAX-1 may provide an additional control point.

Accumulating evidence indicates that regulation of ER Ca2+ homeostasis represents a critical determinant of cellular sensitivity to apoptotic stimuli. Overexpression of the antiapoptotic protein Bcl-2 in HeLa and HEK 293 cells resulted in alterations in Ca<sup>2+</sup> handling, causing significant reduction of ER Ca<sup>2+</sup> levels. This effect was proposed to confer protection against apoptosis by reducing Ca<sup>2+</sup> efflux across ER membrane and preventing sustained Ca<sup>2+</sup> increase in the cytoplasm and mitochondria that would trigger activation of cell death signaling cascades (Lam et al., 1994; Foyouzi-Youssefi et al., 2000; Pinton et al., 2000; Palmer et al., 2004). In addition to Bcl-2, the proapoptotic proteins BAX and BAK have also been shown to influence cell survival through regulation of ER Ca2+ homeostasis and mitochondrial Ca<sup>2+</sup> accumulation (Nutt et al., 2002). Embryonic fibroblast cells from BAX and BAK double knockout mice exhibited reduced resting ER Ca2+ levels, decreased uptake of Ca<sup>2+</sup> by mitochondria after ER Ca<sup>2+</sup> release and resistance to apoptotic stimuli, that release Ca<sup>2+</sup> from intracellular stores (Scorrano et al., 2003). Importantly, overexpression of SERCA in these cells resulted in restoration of ER Ca<sup>2+</sup>

levels and increased susceptibility to apoptotic agents, demonstrating the crucial role of ER  $Ca^{2+}$  content in determining cell survival (Scorrano *et al.*, 2003).

In accordance with the above studies on Bcl-2-related proteins (Lam et al., 1994; Foyouzi-Youssefi et al., 2000; Pinton et al., 2000; Palmer et al., 2004), our findings indicate that HAX-1 may also promote cell survival through modulation of Ca<sup>2+</sup> homeostasis. Indeed, overexpression of HAX-1 in HEK 293 cells resulted in decreased cytosolic Ca<sup>2+</sup> levels, after thapsigargin treatment, suggesting a significant reduction in ER Ca<sup>2+</sup> content. This effect of HAX-1 was abolished upon cotransfection with SERCA2, which counteracts HAX-1's antiapoptotic activity. In agreement with our observations, previous studies also reported that overexpression of SERCA2b in MCF7 breast cancer epithelial cells transfected with Bcl-2 restored ER Ca<sup>2+</sup> content to control levels (Palmer et al., 2004), whereas adenoviral overexpression of SERCA in COS-1 cells resulted in ER Ca<sup>2+</sup> overload (Ma et al., 1999). However, it is likely that additional mechanisms may contribute to the apparent alterations of the ER Ca<sup>2+</sup> content observed in our study as well as previous studies. In this regard, studies on the effects of SERCA's downregulation may provide additional insights on the role of HAX-1 in regulating ER Ca<sup>2+</sup> stores and cell survival.

The reduced Ca<sup>2+</sup> release from ER stores in HAX-1-overexpressing cells is associated with significant down-regulation of SERCA2 expression levels. Similar to our findings, Bcl-2 overexpression also decreased SERCA levels in LNCaP prostate cancer epithelial cells (Vanden Abeele et al., 2002). Conversely, our studies suggest that overexpression of SERCA2 resulted in increases in ER Ca2+ content, diminishing the protective effects of HAX-1. This inhibition of HAX-1's antiapoptotic activity may also be mediated by trapping of HAX-1 by the large size of SERCA2, perhaps preventing its proper localization or folding. Thus, overexpression of HAX-1 or Bcl-2 may promote cell survival by modulation of SERCA levels, resulting in diminished ER Ca<sup>2+</sup> content and protection of mitochondria from Ca<sup>2+</sup> overload. Previous in vitro studies have also indicated that, through direct binding, Bcl-2 inhibits SERCA activity and causes a conformational unfolding of the protein (Dremina et al., 2004), which may be associated with displacement of the enzyme from caveolae-related domains of the SR (Dremina et al., 2006). We also report here that overexpression of HAX-1 is associated with reduced SERCA2 protein in the membrane fraction, which may potentially lead to its degradation in the cytosol by the proteasomal pathway.

In summary, our findings suggest that HAX-1 interacts with SERCA2 in vitro and HAX-1 may down-regulate the SERCA2 protein levels in HEK 293 cells. Importantly, overexpression of HAX-1 was associated with reduction in ER Ca<sup>2+</sup> content and increased cell survival, indicating that the antiapoptotic function of HAX-1 may be partially mediated through regulation of SERCA. However, it is currently unclear whether similar effects occur in striated muscle or whether our findings may be restricted to nonmuscle tissues. Consistent with this, adenoviral overexpression of SERCA2 in COS-1 cells significantly induced apoptosis (Ma et al., 1999), whereas increased SERCA2 expression in transgenic animal hearts or cultured cardiomyocytes did not accelerate apoptosis (Hajjar *et al.,* 1997; He et al., 1997; Baker et al., 1998; Wu et al., 2004). Future studies should be designed to address the role of HAX-1 in ER/SR function in vivo, in muscle and nonmuscle tissues.

### ACKNOWLEDGMENTS

We are grateful to the Biological Imaging Unit at the Biomedical Research Foundation for assistance with confocal imaging. This work was supported by research funds from the Biomedical Research Foundation of the Academy of Athens; the John F. Kostopoulos Foundation; the Hellenic Cardiological Society; National Institutes of Health grants HL26057, HL64018, and HL77101; the Leducq Foundation Trans-Antlantic alliance; and the European Union 6th Framework Program for Research and Technological Development, "Life sciences, genomics and biotechnology for health," VALAPODYN, contract LSHG-CT-2006-037277.

#### REFERENCES

Aga-Mizrachi, S., Brutman-Barazani, T., Jacob, A. I., Bak, A., Elson, A., and Sampson, S. R. (2008). Cytosolic protein tyrosine phosphatase-{epsilon} is a negative regulator of insulin signaling in skeletal muscle. Endocrinology 149, 605–614.

Ahn, W., Lee, M. G., Kim, K. H., and Muallem, S. (2003). Multiple effects of SERCA2b mutations associated with Darier's disease. J. Biol. Chem. 278, 20795–20801.

Arvanitis, D. A., Vafiadaki, E., Fan, G. C., Mitton, B. A., Gregory, K. N., Del Monte, F., Kontrogianni-Konstantopoulos, A., Sanoudou, D., and Kranias, E. G. (2007). Histidine-rich Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase. Am. J. Physiol. Heart Circ. Physiol. 293, H1581–H1589.

Asahi, M., Kimura, Y., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1999). Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites. J. Biol. Chem. 274, 32855–32862.

Asahi, M., McKenna, E., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (2000). Physical interactions between phospholamban and sarco(endo)plasmic reticulum Ca2+-ATPases are dissociated by elevated Ca2+, but not by phospholamban phosphorylation, vanadate, or thapsigargin, and are enhanced by ATP. J. Biol. Chem. 275, 15034–15038.

Asahi, M., Nakayama, H., Tada, M., and Otsu, K. (2003). Regulation of sarco(endo)plasmic reticulum Ca2+ adenosine triphosphatase by phospholamban and sarcolipin: implication for cardiac hypertrophy and failure. Trends Cardiovasc. Med. *13*, 152–157.

Baker, D. L. *et al.* (1998). Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ. Res. *83*, 1205–1214.

Berman, M. C. (2000). Characterisation of thapsigargin-releasable Ca(2+) from the Ca(2+)-ATPase of sarcoplasmic reticulum at limiting [Ca(2+)]. Biochim. Biophys. Acta 1509, 42–54.

Chu, G. *et al.* (1996). Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. 79, 1064–1076.

Cilenti, L., Soundarapandian, M. M., Kyriazis, G. A., Stratico, V., Singh, S., Gupta, S., Bonventre, J. V., Alnemri, E. S., and Zervos, A. S. (2004). Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J. Biol. Chem. 279, 50295–50301.

Csordas, G., and Hajnoczky, G. (2001). Sorting of calcium signals at the junctions of endoplasmic reticulum and mitochondria. Cell Calcium 29, 249–262.

Csordas, G., Renken, C., Varnai, P., Walter, L., Weaver, D., Buttle, K. F., Balla, T., Mannella, C. A., and Hajnoczky, G. (2006). Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol. *174*, 915–921.

Dode, L., Andersen, J. P., Leslie, N., Dhitavat, J., Vilsen, B., and Hovnanian, A. (2003). Dissection of the functional differences between sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses. J. Biol. Chem. 278, 47877–47889.

Dremina, E. S., Sharov, V. S., Kumar, K., Zaidi, A., Michaelis, E. K., and Schoneich, C. (2004). Anti-apoptotic protein Bcl-2 interacts with and destabilizes the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA). Biochem. J. 383, 361–370.

Dremina, E. S., Sharov, V. S., and Schoneich, C. (2006). Displacement of SERCA from SR lipid caveolae-related domains by Bcl-2, a possible mechanism for SERCA inactivation. Biochemistry 45, 175–184.

Dufva, M., Olsson, M., and Rymo, L. (2001). Epstein-Barr virus nuclear antigen 5 interacts with HAX-1, a possible component of the B-cell receptor signalling pathway. J. Gen. Virol. *82*, 1581–1587.

Foyouzi-Youssefi, R., Arnaudeau, S., Borner, C., Kelley, W. L., Tschopp, J., Lew, D. P., Demaurex, N., and Krause, K. H. (2000). Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA 97, 5723–5728.

Gallagher, A. R., Cedzich, A., Gretz, N., Somlo, S., and Witzgall, R. (2000). The polycystic kidney disease protein PKD2 interacts with Hax-1, a protein associated with the actin cytoskeleton. Proc. Natl. Acad. Sci. USA 97, 4017–4022.

Haghighi, K. *et al.* (2006). A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. USA *103*, 1388–1393.

Haghighi, K. *et al.* (2003). Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. *111*, 869–876.

Hajjar, R. J., Kang, J. X., Gwathmey, J. K., and Rosenzweig, A. (1997). Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation *95*, 423–429.

Han, Y., Chen, Y.-S., Liu, Z., Bodyak, N., Rigor, D., Bisping, E., Pu, W. T., and Kang, P. M. (2006). Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition. Circ. Res. 99, 415–423.

Hasenfuss, G., and Pieske, B. (2002). Calcium cycling in congestive heart failure. J. Mol. Cell. Cardiol. 34, 951–969.

Hasenfuss, G. *et al.* (1994). Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434–442.

He, H. *et al.* (1997). Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J. Clin. Invest. *100*, 380–389.

Ihara, Y., Kageyama, K., and Kondo, T. (2005). Overexpression of calreticulin sensitizes SERCA2a to oxidative stress. Biochem. Biophys. Res. Commun. *329*, 1343–1349.

James, P., Inui, M., Tada, M., Chiesi, M., and Carafoli, E. (1989). Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum. Nature 342, 90–92.

Kadambi, V. J., Ponniah, S., Harrer, J. M., Hoit, B. D., Dorn, G. W., 2nd., Walsh, R. A., and Kranias, E. G. (1996). Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97, 533–539.

Kasashima, K., Ohta, E., Kagawa, Y., and Endo, H. (2006). The pleiotropic human prohibitin 2, mitochondrial functions and estrogen receptor-dependent nuclear translocation. J. Biol. Chem. 281, 36401–36410.

Kimura, Y., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1996). Phospholamban regulates the Ca2+-ATPase through intramembrane interactions. J. Biol. Chem. 271, 21726–21731.

Kontrogianni-Konstantopoulos, A., Jones, E. M., Van Rossum, D. B., and Bloch, R. J. (2003). Obscurin is a ligand for small ankyrin 1 in skeletal muscle. Mol. Biol. Cell 14, 1138–1148.

Lam, M., Dubyak, G., Chen, L., Nunez, G., Miesfeld, R. L., and Distelhorst, C. W. (1994). Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc. Natl. Acad. Sci. USA 91, 6569–6573.

Li, C., Fox, C. J., Master, S. R., Bindokas, V. P., Chodosh, L. A., and Thompson, C. B. (2002). Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc. Natl. Acad. Sci. USA 99, 9830– 9835.

Luo, W., Grupp, I. L., Harrer, J., Ponniah, S., Grupp, G., Duffy, J. J., Doetschman, T., and Kranias, E. G. (1994). Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75, 401–409.

Lytton, J., Westlin, M., and Hanley, M. R. (1991). Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J. Biol. Chem. 266, 17067–17071.

Ma, T. S., Mann, D. L., Lee, J. H., and Gallinghouse, G. J. (1999). SR compartment calcium and cell apoptosis in SERCA overexpression. Cell Calcium 26, 25–36.

MacLennan, D. H., Rice, W. J., and Green, N. M. (1997). The mechanism of Ca2+ transport by sarco(endo)plasmic reticulum Ca2+-ATPases. J. Biol. Chem. 272, 28815–28818.

Mannella, C. A., Buttle, K., Rath, B. K., and Marko, M. (1998). Electron microscopic tomography of rat-liver mitochondria and their interaction with the endoplasmic reticulum. Biofactors 225–228.

Meyer, M. et al. (1995). Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778–784.

Nutt, L. K., Pataer, A., Pahler, J., Fang, B., Roth, J., McConkey, D. J., and Swisher, S. G. (2002). Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J. Biol. Chem. 277, 9219– 9225.

Palmer, A. E., Jin, C., Reed, J. C., and Tsien, R. Y. (2004). Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc. Natl. Acad. Sci. USA *101*, 17404–17409.

Pinton, P., Ferrari, D., Magalhaes, P., Schulze-Osthoff, K., Di Virgilio, F., Pozzan, T., and Rizzuto, R. (2000). Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J. Cell Biol. *148*, 857–862.

Rizzuto, R., Pinton, P., Carrington, W., Fay, F. S., Fogarty, K. E., Lifshitz, L. M., Tuft, R. A., and Pozzan, T. (1998). Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 280, 1763–1766.

Sagara, Y., and Inesi, G. (1991). Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. J. Biol. Chem. 266, 13503–13506.

Schmitt, J. P. *et al.* (2003). Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410–1413.

Scorrano, L., Oakes, S. A., Opferman, J. T., Cheng, E. H., Sorcinelli, M. D., Pozzan, T., and Korsmeyer, S. J. (2003). BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 300, 135–139.

Sharp, T. V., Wang, H. W., Koumi, A., Hollyman, D., Endo, Y., Ye, H., Du, M. Q., and Boshoff, C. (2002). K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with anti-apoptotic function. J. Virol. 76, 802–816.

Simmerman, H. K., and Jones, L. R. (1998). Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. 78, 921–947.

Simpson, P. B., and Russell, J. T. (1997). Role of sarcoplasmic/endoplasmic-reticulum Ca2+-ATPases in mediating Ca2+ waves and local Ca2+-release microdomains in cultured glia. Biochem. J. 325, 239–247.

Slack, J. P. et al. (2001). The enhanced contractility of the phospholambandeficient mouse heart persists with aging. J. Mol. Cell. Cardiol. 33, 1031–1040.

Suzuki, Y., Demoliere, C., Kitamura, D., Takeshita, H., Deuschle, U., and Watanabe, T. (1997). HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family of tyrosine kinases. J. Immunol. *158*, 2736–2744.

Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, A. P. (1990). Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc. Natl. Acad. Sci. USA *87*, 2466–2470.

Toyofuku, T., Kurzydlowski, K., Lytton, J., and MacLennan, D. H. (1992). The nucleotide binding/hinge domain plays a crucial role in determining isoform-specific Ca2+ dependence of organellar Ca(2+)-ATPases. J. Biol. Chem. 267, 14490–14496.

Toyofuku, T., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1993). Identification of regions in the Ca(2+)-ATPase of sarcoplasmic reticulum that affect functional association with phospholamban. J. Biol. Chem. 268, 2809–2815.

Toyofuku, T., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1994a). Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca(2+)-ATPase of sarcoplasmic reticulum. J. Biol. Chem. 269, 3088–3094.

Toyofuku, T., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1994b). Amino acids Lys-Asp-Asp-Lys-Pro-Val402 in the Ca(2+)-ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban. J. Biol. Chem. 269, 22929–22932.

Toyoshima, C., Asahi, M., Sugita, Y., Khanna, R., Tsuda, T., and MacLennan, D. H. (2003). Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase. Proc. Natl. Acad. Sci. USA *100*, 467–472.

Toyoshima, C., Nakasako, M., Nomura, H., and Ogawa, H. (2000). Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature 405, 647–655.

Toyoshima, C., Sasabe, H., and Stokes, D. L. (1993). Three-dimensional cryoelectron microscopy of the calcium ion pump in the sarcoplasmic reticulum membrane. Nature *362*, 467–471.

Vafiadaki, E., Papalouka, V., Arvanitis, D. A., Kranias, E. G., and Sanoudou, D. (2008). The role of SERCA2a/PLN complex, Ca(2+) homeostasis, and anti-apoptotic proteins in determining cell fate. Pflugers Arch. (*in press*).

Vafiadaki, E., Sanoudou, D., Arvanitis, D. A., Catino, D. H., Kranias, E. G., and Kontrogianni-Konstantopoulos, A. (2007). Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J. Mol. Biol. 367, 65–79.

Vanden Abeele, F., Skryma, R., Shuba, Y., Van Coppenolle, F., Slomianny, C., Roudbaraki, M., Mauroy, B., Wuytack, F., and Prevarskaya, N. (2002). Bcl-2dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 1, 169–179.

Vangheluwe, P., Raeymaekers, L., Dode, L., and Wuytack, F. (2005). Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium *38*, 291–302.

Wu, G., Long, X., and Marin-Garcia, J. (2004). Adenoviral SERCA1 overexpression triggers an apoptotic response in cultured neonatal but not in adult rat cardiomyocytes. Mol. Cell. Biochem. 267, 123–132.

Yedavalli, V. S. *et al.* (2005). Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J. Virol. 79, 13735–13746.

Zhang, P., Toyoshima, C., Yonekura, K., Green, N. M., and Stokes, D. L. (1998). Structure of the calcium pump from sarcoplasmic reticulum at 8-A resolution. Nature 392, 835–839.